Skip to main content

Posterior Urethral Valves

Posterior urethral valves (PUV) are the most common cause of congenital lower urinary tract obstruction in males, with an incidence of roughly 1 in 3,800–5,000 live-born boys.[1] They are classically a prenatal or infant diagnosis, but PUV is a lifelong disease: obstruction is relieved in infancy, yet the renal and bladder consequences continue to evolve for decades, frequently worsening at puberty and into adult life.[1][6]

For the adult reconstructive and functional urologist this is not a pediatric diagnosis left behind in childhood. These men arrive with progressive chronic kidney disease, a decompensating "valve bladder," catheterizable channels and augmentations placed years earlier, fertility and sexual-health questions, and — too often — a gap in care after they aged out of pediatric urology. Management of adults with congenital uropathy has been argued to be "a specialty in its own right."[9] This article therefore sits within Transitional Urology rather than under voiding & outlet disorders.

Why PUV Persists into Adulthood​

PUV management spans fetal life through adulthood and demands a multidisciplinary approach — urology, nephrology, transition coordination, and psychosocial support — with long-term follow-up to monitor renal function, manage bladder dysfunction, and prevent complications.[1] Two features make it a lifelong problem:

  • Renal injury is set in utero but progresses postnatally. Roughly half of patients with damaged kidneys at birth remain stable through childhood, after which about half deteriorate around puberty.[9]
  • The bladder never fully normalizes. Sustained postnatal changes drive the "valve bladder" phenotype, which evolves from a small, overactive, poorly compliant bladder in infancy toward an oversized, poorly emptying, myogenically failed bladder later in life.[13]

Transitional urology — bridging pediatric and adult care — is recognized as one of the highest-priority research topics in urology, and the transition window itself is a period of heightened risk: more emergency visits after age 18, persistent bothersome urinary symptoms, and gaps in appropriate management.[2]

Delayed and Adult Presentation​

Although most PUV is detected prenatally or in infancy, a subset presents late — in childhood, adolescence, or adulthood. In a multi-institutional review of 47 patients diagnosed between ages 5 and 35, the most common presenting symptoms were diurnal enuresis (60%), urinary tract infection (40%), and voiding pain (13%); less common were poor stream, gross hematuria, and proteinuria.[3] At late diagnosis, hydronephrosis was present in 40%, vesicoureteral reflux in 33%, elevated serum creatinine in 35%, and ESRD in 10%.[3] Rarely, PUV is first recognized in adult men presenting with obstructive symptoms, prostatitis-like complaints, or end-stage renal failure after years of unrecognized obstruction.[4][5]

Practice point. Consider voiding cystourethrography (VCUG) in any male with unexplained voiding complaints — particularly enuresis or recurrent UTIs — even into adulthood; the diagnosis is missed precisely because it is not considered.[3]

Long-Term Renal Outcomes​

Renal function is the single most important lifelong concern. Approximately one-third of PUV patients reach ESRD before adulthood, and function continues to decline thereafter.[1][8] In a cohort followed a median of 22.7 years (median age 26 at last contact), 46.1% had ESRD (35.9% transplanted), 5.1% had CKD, and 48.7% retained normal GFR.[7] Annualized eGFR decline is estimated at about 2.6 mL/min/1.73 m²/year, with both children and adults showing progressive loss.[6]

The two dominant modifiable accelerators are proteinuria and recurrent febrile UTIs.[6] Proteinuria in particular is a critical surveillance marker — any urologist following these patients should screen for it routinely, as it signals renal deterioration; glomerular and tubular markers both track with renal outcome.[9][10] RAS inhibition can slow but does not prevent progression to ESRD (see Renal Preservation).[9]

Valve Bladder Syndrome​

The "valve bladder syndrome" — coined by Mitchell in 1982 — describes persistent, severely impaired bladder dynamics despite successful valve ablation.[11][12] The pathophysiology is a self-reinforcing triad of sustained bladder overdistention:[12]

  • Polyuria from a nephrogenic concentrating defect
  • Impaired bladder sensation
  • Incomplete emptying with significant residual urine

These synergize to prevent bladder normalization, progressively reduce functional capacity, and drive bladder decompensation, upper-tract dilation, and further renal injury.[12] Bladder dysfunction is reported in 38–90% of PUV patients depending on cohort and follow-up.[7][11] The phenotype evolves with age: low compliance and detrusor overactivity dominate in infancy; later the bladder tends to become oversized with poor emptying (myogenic failure).[13] Secondary bladder-neck hypertrophy can contribute to outlet resistance and emptying failure.[14]

Bladder Management​

Bladder dysfunction is a major modifiable driver of renal deterioration, so its management is the cornerstone of adult PUV care and follows a stepwise escalation.

Step 1 — Behavioral and conservative measures​

  • Timed and double voiding to minimize residual urine.
  • Nocturnal bladder emptying — the single most impactful intervention for valve bladder. Koff et al. showed that overnight drainage (indwelling night catheter, intermittent nocturnal catheterization, or frequent nocturnal double voiding) produces prompt, often dramatic improvement or elimination of hydronephrosis — comparable to diversion. Daytime CIC alone is insufficient because polyuria and impaired sensation leave the bladder overdistended all night.[12]
  • Clean intermittent catheterization (CIC) for significant post-void residuals. Early CIC can counteract functional decline: in one series boys on CIC had a median GFR change of +7%, versus −24% in those who discontinued it; CIC is in use in roughly 26% of PUV patients by age 10.[15][16]

Step 2 — Pharmacotherapy​

Drug classAgentsIndication / rationaleNotes
AntimuscarinicsOxybutynin, solifenacin, tolterodineDetrusor overactivity, poor complianceImprove compliance and continence and can resolve secondary VUR; risk of precipitating myogenic failure — monitor PVR and urodynamics[17]
Alpha-1 blockersTamsulosin, doxazosinSecondary bladder-neck obstruction / functional outlet resistanceModest improvement in Qmax and emptying[14]
Combination (antimuscarinic + alpha-blocker)—Storage + voiding dysfunction togetherPilot RCT after valve ablation showed the most consistent favorable urodynamic pattern (capacity, Pdet), though between-group differences were not significant[18]
β3-agonistsMirabegron, vibegronStorage symptoms, especially with anticholinergic intoleranceBetter cognitive-safety profile; emerging NLUTD evidence

Anticholinergics are not benign here: in one urodynamics-guided series, 2 of 21 patients developed new myogenic failure requiring CIC after starting an antimuscarinic — close urodynamic monitoring is mandatory.[17]

Step 3 — Intravesical onabotulinumtoxinA​

For detrusor overactivity or poor compliance refractory to oral therapy, intravesical onabotulinumtoxinA is an emerging intermediate option before augmentation. In a preliminary PUV-specific cohort it resolved detrusor overactivity in 10 of 11 patients (peak DO pressure median 47 → 0 cmH₂O, p = 0.004), improved compliance (median +6.1 mL/cmH₂O), and improved VUR in 6 of 8 renal units.[19] It may delay or avoid augmentation but requires repeat injections, and PUV-specific evidence remains preliminary. The AUA/SUFU NLUTD guideline supports onabotulinumtoxinA for refractory detrusor overactivity, with the caveat that spontaneously voiding patients must be counseled about urinary retention risk.[20]

Step 4 — Bladder augmentation ± catheterizable channel​

Augmentation cystoplasty (usually ileocystoplasty), with or without a Mitrofanoff continent catheterizable channel, is the definitive option for refractory valve bladder.[20][21]

  • Indication — capacity, compliance, or detrusor overactivity refractory to medications and botulinum toxin.[20][21]
  • Outcome — Mitrofanoff with CIC and overnight drainage significantly improves hydronephrosis (mean renal-pelvis AP diameter −14.2 mm, p ≤ 0.001) and compliance (poor compliance 75% → 28.6%, p = 0.014). Crucially, it does not prevent renal deterioration — ESRD still developed in 35% during follow-up despite improved urodynamics.[22]
  • Burden — bowel-incorporating reconstruction commits the patient to lifelong surveillance: metabolic acidosis, vitamin B12 deficiency (ileal segments), stones, mucus, perforation risk, and a small long-term malignancy risk. See Transitional Urology → augmentation surveillance and Bladder Augmentation.
  • Approach — laparoscopic / robot-assisted Mitrofanoff and continent diversion are feasible and safe in adults.[23]

Renal Preservation​

Renal preservation is the overriding lifelong goal and is co-managed with nephrology. The reconstructive urologist's job is to keep the lower tract a safe, low-pressure reservoir and to ensure the medical nephroprotective backbone is in place.

  • RAS inhibition (ACE inhibitor / ARB) is the pharmacologic backbone in PUV patients with proteinuria — uptitrated to maximum tolerated dose, continued even as eGFR falls, with potassium and creatinine monitored rather than reflexively stopping therapy.[9][24]
  • SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce kidney-failure risk by roughly one-third across the spectrum of eGFR and albuminuria regardless of diabetes status; KDIGO 2024 recommends them for CKD at eGFR ≥ 20 mL/min/1.73 m². No PUV-specific trials exist, but the benefit appears independent of primary kidney diagnosis.[24][25]
  • Proteinuria is the most important modifiable predictor of decline — screen at least annually with urine ACR and intensify RAS / SGLT2 therapy when it appears.[6][24]
  • Blood pressure — hypertension is common and accelerates renal loss; treat to guideline targets.[24]
  • Polyuria / concentrating defect — many PUV patients have a nephrogenic concentrating defect producing polyuria (often >2 L/day) that drives bladder overdistention. Oral desmopressin reduces daily urine output and improves urine concentration, with the best responses in those with significant bladder dysfunction; pairing it with overnight catheterization can be especially effective. Monitor sodium — hyponatremia is the principal risk.[26]

Renal Transplantation and Bladder Optimization​

For the large minority who reach ESRD, transplantation is the treatment of choice — but the valve bladder follows the graft, and a hostile lower tract is what distinguishes PUV transplantation from transplantation for other causes.

  • Short-term graft survival is comparable to non-urologic causes (~70% at 10 years), but 20-year graft survival is worse in PUV / CAKUT (≈30% vs 49–53%), attributed to ongoing bladder dysfunction.[27]
  • PUV recipients have lower post-transplant eGFR at 1–10 years, far more frequent UTIs, and earlier progression to advanced CKD than non-urologic controls.[28]
  • Graft survival is similar across native bladder, augmented bladder, and continent / incontinent diversion — provided bladder management is well conducted — although enterocystoplasty and continent diversions expose grafts to more frequent acute pyelonephritis.[29]
  • Pre-transplant bladder optimization is critical: confirm adequate capacity and compliance, establish CIC where needed, and augment a hostile bladder before transplantation rather than after.[30]

Sexual and Reproductive Outcomes​

A systematic review of 11 studies (2,723 individuals) found that most males treated for PUV in childhood reach adulthood with preserved erectile and ejaculatory function.[32] Erectile dysfunction is rare — none in one adult series — while ejaculatory abnormalities (slow ejaculation) were reported in about 12.5%.[7] Semen parameters are normal in roughly half of cohorts, with abnormalities clustering in those with renal impairment.[32] Paternity rates vary widely (6–58%) but appear comparable to the general population in Finnish data (49% had fathered children, similar to age-matched controls); renal failure and urinary incontinence are the chief factors associated with reduced paternity.[33][34] Lower urinary tract symptoms are common and may erode sexual self-efficacy — worth addressing proactively during transition.[35]

Transition from Pediatric to Adult Care​

The transition window is a vulnerable one — adolescents with PUV have an overwhelming desire to be "normal" and may disengage from follow-up just as their renal and bladder trajectories enter the high-risk pubertal period.[2][9]

Key challenges

  • Loss to follow-up driven by the drive for normalcy and the move away from a familiar pediatric team.[9]
  • Lack of standardized transition protocols and transition coordinators across systems.
  • Many adult urologists are unfamiliar with the nuances of congenital uropathy and reconstructed anatomy.[9][37]

What works

  • Dedicated multidisciplinary clinics combining pediatric and adult urology, nephrology, and psychosocial support, with a transition coordinator.[2]
  • Structured pathways and psychosocial-readiness assessment — health literacy and family support are the primary predictors of successful transition.
  • Proactive, not reactive, management. A dedicated standardized PUV clinic reduced CKD progression (12% vs 27%, p = 0.02) and kidney-replacement therapy (3% vs 20%, p < 0.05) compared with traditional care — the current best-practice model for lifelong PUV management.[36]

Lifelong Surveillance​

DomainFrequencyMethod
Renal function (eGFR, creatinine)Every 6–12 monthsSerum creatinine ± cystatin C[1][6]
ProteinuriaEvery 6–12 monthsUrine ACR — the key predictor of decline[6][10]
Bladder functionAnnuallyUroflow, PVR, bladder diary; noninvasive urodynamics is as effective as invasive for routine surveillance, with invasive studies reserved for progressive deterioration[31]
Blood pressureEvery visitOffice ± ambulatory[24]
Renal imagingAnnuallyUltrasound (hydronephrosis, renal size)[1]
Metabolic panel (if augmented)Every 6–12 monthsBlood gas, B12, electrolytes[20]
UTI surveillanceOngoingCulture if symptomatic; prophylaxis if recurrent febrile UTIs[6]
Sexual / reproductive healthPeriodicallySymptom assessment, semen analysis if fertility desired[32]
Psychosocial / QoLPeriodicallyValidated questionnaires[32]

Key Principles​

  • PUV is a lifelong disease, not a neonatal event. Renal and bladder function frequently deteriorate at puberty and into adulthood; surveillance must continue across the life course.[1][9]
  • Proteinuria and recurrent febrile UTIs are the modifiable accelerators of renal loss — screen for and treat both.[6]
  • Nocturnal bladder emptying is the highest-yield intervention for valve bladder — daytime CIC alone is insufficient against overnight polyuria.[12]
  • Stepwise bladder management — behavioral / CIC → antimuscarinic ± alpha-blocker → intravesical botulinum → augmentation with catheterizable channel — but augmentation improves urodynamics without guaranteeing renal preservation.[18][19][22]
  • Optimize the bladder before transplantation, not after — graft survival depends on a safe, low-pressure reservoir.[29][30]
  • Most men retain erectile and ejaculatory function and can father children; reduced paternity tracks with renal failure and incontinence.[32][33]
  • A standardized, proactive multidisciplinary PUV clinic roughly halves CKD progression and kidney-replacement therapy versus reactive care.[36]

See Also​

References​

1. El-Ghoneimi A, Harper L, Pierucci UM, et al. "Management of Patients With Posterior Urethral Valves 'From the Fetus to Adolescence': French National Diagnostic and Care Protocol (NDCP)." Orphanet J Rare Dis. 2025;20(1):225. doi:10.1186/s13023-025-03712-5

2. Lopez AD, Kalaga I, Copp HL, Shaw NM, Hampson LA. "Transitional Urology: A Comprehensive Review of the Transitional Care Process." Nat Rev Urol. 2026. doi:10.1038/s41585-026-01152-9

3. Bomalaski MD, Anema JG, Coplen DE, et al. "Delayed Presentation of Posterior Urethral Valves: A Not So Benign Condition." J Urol. 1999;162(6):2130-2132. doi:10.1016/S0022-5347(05)68140-2

4. Mueller SC, Marshall FF. "Spectrum of Unrecognized Posterior Urethral Valves in the Adult." Urology. 1983;22(2):139-142. doi:10.1016/0090-4295(83)90495-8

5. Saraf PG, Valvo JR, Frank IN. "Congenital Posterior Urethral Valves in an Adult." Urology. 1984;23(1):55-57.

6. Huang VW, Behairy M, Abelson B, et al. "Kidney Disease Progression in Pediatric and Adult Posterior Urethral Valves (PUV) Patients." Pediatr Nephrol. 2024;39(3):829-835. doi:10.1007/s00467-023-06128-0

7. Çetin B, Dönmez Mİ, Erdem S, Ziylan O, Oktar T. "Renal, Bladder and Sexual Outcomes in Adult Men With History of Posterior Urethral Valves Treated in Childhood." Urology. 2021;153:301-306. doi:10.1016/j.urology.2020.11.002

8. Heikkilä J, Holmberg C, Kyllönen L, Rintala R, Taskinen S. "Long-Term Risk of End Stage Renal Disease in Patients With Posterior Urethral Valves." J Urol. 2011;186(6):2392-2396. doi:10.1016/j.juro.2011.07.109

9. Woodhouse CR, Neild GH, Yu RN, Bauer S. "Adult Care of Children From Pediatric Urology." J Urol. 2012;187(4):1164-1171. doi:10.1016/j.juro.2011.12.011

10. Heikkilä J, Jahnukainen T, Holmberg C, Taskinen S. "Association of Renal Glomerular and Tubular Function With Renal Outcome in Patients With Posterior Urethral Valves." Urology. 2021;153:285-290. doi:10.1016/j.urology.2020.11.045

11. Glassberg KI. "The Valve Bladder Syndrome: 20 Years Later." J Urol. 2001;166(4):1406-1414.

12. Koff SA, Mutabagani KH, Jayanthi VR. "The Valve Bladder Syndrome: Pathophysiology and Treatment With Nocturnal Bladder Emptying." J Urol. 2002;167(1):291-297. doi:10.1016/s0022-5347(05)65453-5

13. Taskinen S, Heikkilä J, Rintala R. "Effects of Posterior Urethral Valves on Long-Term Bladder and Sexual Function." Nat Rev Urol. 2012;9(12):699-706. doi:10.1038/nrurol.2012.196

14. Androulakakis PA, Karamanolakis DK, Tsahouridis G, Stefanidis AA, Palaeodimos I. "Myogenic Bladder Decompensation in Boys With a History of Posterior Urethral Valves Is Caused by Secondary Bladder Neck Obstruction?" BJU Int. 2005;96(1):140-143. doi:10.1111/j.1464-410X.2005.05583.x

15. Holmdahl G, Sillen U, Hellström AL, Sixt R, Sölsnes E. "Does Treatment With Clean Intermittent Catheterization in Boys With Posterior Urethral Valves Affect Bladder and Renal Function?" J Urol. 2003;170(4 Pt 2):1681-1685. doi:10.1097/01.ju.0000084142.71123.b5

16. McLeod DJ, Szymanski KM, Gong E, et al. "Renal Replacement Therapy and Intermittent Catheterization Risk in Posterior Urethral Valves." Pediatrics. 2019;143(3):e20182656. doi:10.1542/peds.2018-2656

17. Kim YH, Horowitz M, Combs AJ, et al. "Management of Posterior Urethral Valves on the Basis of Urodynamic Findings." J Urol. 1997;158(3 Pt 2):1011-1016. doi:10.1097/00005392-199709000-00085

18. Singhai P, Malik MA, Mahajan JK. "Effect of Anticholinergics vs. Alpha-1 Blockers vs. Combination Therapy on Bladder Function in Patients With Posterior Urethral Valve After Transurethral Fulguration: A Pilot Randomized Controlled Trial." Pediatr Surg Int. 2026;42(1):226. doi:10.1007/s00383-026-06467-7

19. Mohan Kunnath S, Solomon E, Mishra P, et al. "Intravesical Botulinum Toxin Injection for Treating Detrusor Overactivity and Poor Compliance in Posterior Urethral Valves — A Preliminary Experience." Neurourol Urodyn. 2025;44(4):760-767. doi:10.1002/nau.70039

20. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." J Urol. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239

21. Cheng PJ, Myers JB. "Augmentation Cystoplasty in the Patient With Neurogenic Bladder." World J Urol. 2020;38(12):3035-3046. doi:10.1007/s00345-019-02919-z

22. King T, Coleman R, Parashar K. "Mitrofanoff for Valve Bladder Syndrome: Effect on Urinary Tract and Renal Function." J Urol. 2014;191(5 Suppl):1517-1522. doi:10.1016/j.juro.2013.09.008

23. Rey D, Helou E, Oderda M, et al. "Laparoscopic and Robot-Assisted Continent Urinary Diversions (Mitrofanoff and Yang-Monti Conduits) in a Consecutive Series of 15 Adult Patients: The Saint Augustin Technique." BJU Int. 2013;112(7):953-958. doi:10.1111/bju.12257

24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease." Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018

25. Neuen BL, Fletcher RA, Anker SD, et al. "SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria." JAMA. 2026;335(3):233-244. doi:10.1001/jama.2025.20834

26. Naghizadeh S, Kefi A, Dogan HS, et al. "Effectiveness of Oral Desmopressin Therapy in Posterior Urethral Valve Patients With Polyuria and Detection of Factors Affecting the Therapy." Eur Urol. 2005;48(5):819-825. doi:10.1016/j.eururo.2005.05.019

27. McKay AM, Kim S, Kennedy SE. "Long-Term Outcome of Kidney Transplantation in Patients With Congenital Anomalies of the Kidney and Urinary Tract." Pediatr Nephrol. 2019;34(11):2409-2415. doi:10.1007/s00467-019-04300-z

28. Rickard M, Chua ME, Robinson CH, et al. "Post-Transplant Kidney Function Decline in Children With Posterior Urethral Valves Versus Non-Urologic Etiologies: Roles of Catheterization, Infection, and Rejection." Pediatr Nephrol. 2026. doi:10.1007/s00467-026-07361-z

29. Marchal S, Kalfa N, Iborra F, et al. "Long-Term Outcome of Renal Transplantation in Patients With Congenital Lower Urinary Tract Malformations: A Multicenter Study." Transplantation. 2020;104(1):165-171. doi:10.1097/TP.0000000000002746

30. DeFoor W, Tackett L, Minevich E, et al. "Successful Renal Transplantation in Children With Posterior Urethral Valves." J Urol. 2003;170(6 Pt 1):2402-2404. doi:10.1097/01.ju.0000089773.40598.b3

31. Capitanucci ML, Marciano A, Zaccara A, et al. "Long-Term Bladder Function Followup in Boys With Posterior Urethral Valves: Comparison of Noninvasive vs Invasive Urodynamic Studies." J Urol. 2012;188(3):953-957. doi:10.1016/j.juro.2012.04.121

32. Gnech M, Pakkasjärvi N, 't Hoen L, et al. "Long-Term Sexual Function, Fertility, and Quality of Life After Childhood Treatment for Posterior Urethral Valves: A Systematic Review of Clinical Outcomes." J Sex Med. 2026;23(3):qdag035. doi:10.1093/jsxmed/qdag035

33. Taskinen S, Heikkilä J, Santtila P, Rintala R. "Posterior Urethral Valves and Adult Sexual Function." BJU Int. 2012;110(8 Pt B):E392-E396. doi:10.1111/j.1464-410X.2012.11091.x

34. Holmdahl G, Sillén U. "Boys With Posterior Urethral Valves: Outcome Concerning Renal Function, Bladder Function and Paternity at Ages 31 to 44 Years." J Urol. 2005;174(3):1031-1034. doi:10.1097/01.ju.0000170233.87210.4f

35. Zöhrer PI, Vauth F, Jaekel AK, Rösch WH, Hofmann A. "Navigating Life With Posterior Urethral Valves — Sexual Health and Lower Urinary Tract Symptoms." J Clin Med. 2024;13(15):4380. doi:10.3390/jcm13154380

36. Rickard M, Lorenzo AJ, Robinson C, et al. "Impact of a Standardized Care Pathway and a Dedicated Multidisciplinary Posterior Urethral Valve Clinic on 5-Year Kidney and Bladder Outcomes." Pediatr Nephrol. 2025. doi:10.1007/s00467-025-06864-5

37. Wiener JS, Huck N, Blais AS, et al. "Challenges in Pediatric Urologic Practice: A Lifelong View." World J Urol. 2021;39(4):981-991. doi:10.1007/s00345-020-03203-1